8-KOther Events

BeOne Medicines Ltd. 8-K Report, Corporate Update (Aug 21, 2019)

Filed August 21, 2019For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) announced on August 21, 2019, that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zanubrutinib for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy. This acceptance represents a significant step forward in the drug's potential market entry, following its earlier designation as a Breakthrough Therapy by the FDA for the same indication. The FDA has granted Priority Review for this NDA, indicating the agency believes zanubrutinib meets its criteria for accelerated review. The Prescription Drug User Fee Act (PDUFA) target action date has been set for February 27, 2020, providing investors with a clear timeline for a potential approval decision. This development is crucial for BeiGene as it advances its pipeline and moves closer to commercialization for this important oncology drug.

Key Highlights

  • 1FDA accepted New Drug Application (NDA) for zanubrutinib for MCL.
  • 2Zanubrutinib is indicated for MCL patients with at least one prior therapy.
  • 3FDA granted Priority Review status for the zanubrutinib NDA.
  • 4PDUFA target action date set for February 27, 2020.
  • 5This follows a prior Breakthrough Therapy designation for zanubrutinib in MCL.
  • 6The announcement was made via press release filed as an exhibit to the 8-K.

Frequently Asked Questions

This 8-K filing announces that the U.S. Food and Drug Administration (FDA) has accepted BeiGene, Ltd.'s New Drug Application (NDA) for zanubrutinib for the treatment of mantle cell lymphoma (MCL) and has granted it Priority Review.

Zanubrutinib is a drug for which BeiGene is seeking approval. This filing specifically concerns its application for treating patients with mantle cell lymphoma (MCL) who have already undergone at least one prior therapy.

Priority Review means the FDA has determined that the drug's potential to be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. This typically leads to an expedited review process. The target action date set by the FDA is February 27, 2020.

Yes, prior to this NDA acceptance and Priority Review, zanubrutinib had received a Breakthrough Therapy designation from the FDA for the treatment of MCL in patients who have received at least one prior therapy.